Ildiko Konrad
Overview
Explore the profile of Ildiko Konrad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Novotny J, Chandraratne S, Weinberger T, Philippi V, Stark K, Ehrlich A, et al.
PLoS One
. 2018 Jan;
13(1):e0190728.
PMID: 29293656
Aims: Medical treatment of arterial thrombosis is mainly directed against platelets and coagulation factors, and can lead to bleeding complications. Novel antithrombotic therapies targeting immune cells and neutrophil extracellular traps...
2.
Echtler K, Konrad I, Lorenz M, Schneider S, Hofmaier S, Plenagl F, et al.
PLoS One
. 2017 Mar;
12(3):e0172788.
PMID: 28253287
Platelets modulate the process of cancer metastasis. However, current knowledge on the direct interaction of platelets and tumor cells is mostly based on findings obtained in vitro. We addressed the...
3.
Petzold T, Thienel M, Konrad I, Schubert I, Regenauer R, Hoppe B, et al.
Sci Transl Med
. 2016 Dec;
8(367):367ra168.
PMID: 27903864
In patients with atrial fibrillation, oral anticoagulation with oral thrombin inhibitors (OTIs), in contrast to vitamin K antagonists (VKAs), associates with a modest increase in acute coronary syndromes (ACSs). Whether...
4.
Chandraratne S, von Bruehl M, Pagel J, Stark K, Kleinert E, Konrad I, et al.
Arterioscler Thromb Vasc Biol
. 2015 Jan;
35(3):589-97.
PMID: 25550202
Objective: Arteriogenesis is strongly dependent on the recruitment of leukocytes, especially monocytes, into the perivascular space of growing collateral vessels. On the basis of previous findings that platelets are central...
5.
Schonberger T, Ziegler M, Borst O, Konrad I, Nieswandt B, Massberg S, et al.
Am J Physiol Cell Physiol
. 2012 Jul;
303(7):C757-66.
PMID: 22814400
Platelets play a critical role in the pathophysiology of reperfusion, sepsis, and cardiovascular diseases. In a multiple step process, they adhere to activated endothelium and release proinflammatory cytokines thereby promoting...
6.
von Bruhl M, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al.
J Exp Med
. 2012 Mar;
209(4):819-35.
PMID: 22451716
Deep vein thrombosis (DVT) is a major cause of cardiovascular death. The sequence of events that promote DVT remains obscure, largely as a result of the lack of an appropriate...
7.
Massberg S, Grahl L, von Bruehl M, Manukyan D, Pfeiler S, Goosmann C, et al.
Nat Med
. 2010 Aug;
16(8):887-96.
PMID: 20676107
Blood neutrophils provide the first line of defense against pathogens but have also been implicated in thrombotic processes. This dual function of neutrophils could reflect an evolutionarily conserved association between...
8.
Bultmann A, Li Z, Wagner S, Peluso M, Schonberger T, Weis C, et al.
J Mol Cell Cardiol
. 2010 May;
49(3):532-42.
PMID: 20430036
Glycoprotein VI (GPVI) mediates binding of platelets to subendothelial collagen during acute arterial thrombosis. GPVI interactions with the activated atherosclerotic vascular endothelium during early atherosclerosis, however, are not well understood....
9.
Reinhardt C, von Bruhl M, Manukyan D, Grahl L, Lorenz M, Altmann B, et al.
J Clin Invest
. 2008 Feb;
118(3):1110-22.
PMID: 18274674
The activation of initiator protein tissue factor (TF) is likely to be a crucial step in the blood coagulation process, which leads to fibrin formation. The stimuli responsible for inducing...
10.
Schulz C, Konrad I, Sauer S, Orschiedt L, Koellnberger M, Lorenz R, et al.
Thromb Haemost
. 2008 Jan;
99(1):190-5.
PMID: 18217153
Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis. However, their impact on atherosclerotic lesion development remains...